RxDoctor Payments DataLook up a doctor →

Juan Loy, MD

Internal Medicine · Margate, FLNPI 1457493157

Payments from drug & device makers

$4,702,818in general payments, 2019–2025

Across 431 payments — averaging $10,911 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$3.9M
  • AbbVie$394K
  • Amgen$386K
  • AstraZeneca$20K
  • Regeneron$13K
  • Alnylam Pharmaceuticals Inc.$9K
  • plus $4K from 36 others
$61,626in research payments, 2019–2025

Across 16 payments — averaging $3851.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$62K

What the payments were for

  • Food & beverage$4,80299%
  • Gifts$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,702,818 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$82,236
Medicare patients
218
Services billed
1,298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin114$148,682
MounjaroTirzepatide139$145,572
JanuviaSitagliptin Phosphate55$77,380
EliquisApixaban73$74,127
TradjentaLinagliptin39$57,645
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$48,730
TrulicityDulaglutide38$45,599
XareltoRivaroxaban31$39,147
Repatha SureclickEvolocumab40$34,445
OzempicSemaglutide16$26,557
Tresiba Flextouch U-200Insulin Degludec14$26,136
FarxigaDapagliflozin Propanediol19$24,913
JanumetSitagliptin Phos/Metformin Hcl15$24,647
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$19,270
Repatha SyringeEvolocumab23$16,672

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$192$211,659164 claims
Lilly USA, LLCMounjaro, Trulicity$350$191,170177 claims
MerckJanuvia, Janumet$70$102,02770 claims
PfizerEliquis$263$74,12773 claims
GileadGenvoya$184$48,73012 claims
Johnson & JohnsonXarelto$135$39,14731 claims
Novo NordiskOzempic$691$26,55716 claims
AstraZenecaFarxiga$19,773$24,91319 claims
GSKTrelegy Ellipta$181$19,27020 claims
AbbVieSynthroid$393,805$5,01143 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Margate

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →